ASCPT 2021 Poster: A First in Human (FIH) Study to Assess the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses, and Alternative Formulations of R941552 (R552): A selective Receptor Interacting Protein 1 (RIP1) Kinase Inhibitor
Overview
Download Quotient Sciences' ASCPT 2021 poster, 'A FIH Study to Assess R941552 (R552): A selective Receptor Interacting Protein 1 (RIP1) Kinase Inhibitor'.
- RIPK1 (receptor interacting serine/threonine kinase 1) mediates cell survival through NF kB, or cell death through apoptosis or
necroptosis downstream of TNF receptor activation. - R552 is a potent and selective RIPK1 inhibitor that has been shown to block inflammatory cell death (necrotosis)
- R552 is being developed for the treatment of autoimmune and inflammatory disorders.
- Preclinical data suggested that solubility may limit exposure; alternative formulations were
also assessed in this first in human (FIH) study.